Analyst Kostas Biliouris of BMO Capital maintained a Buy rating on Korro Bio (KRRO – Research Report), retaining the price target of $120.00.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight Korro Bio’s promising prospects. The ongoing KRRO-110 HV trial has shown positive progress, with safe dosing completion in the initial cohorts and the absence of adverse effects, which bolsters confidence in the safety and potential utilization of KRRO-110. This development, coupled with the significant market-cap difference between Korro Bio and its competitor BEAM, presents an arbitrage opportunity that investors might find appealing.
Furthermore, the potential of KRRO-110 to address Alpha-1 Antitrypsin Deficiency (AATD) is noteworthy, especially considering the high unmet need and lack of approved disease-modifying therapies for this condition. The anticipated readout in the second half of 2025 could reveal therapeutically relevant exposure levels, enhancing the commercial opportunity for KRRO-110. Additionally, Korro Bio’s leadership in RNA editing and its pipeline targeting other conditions like Parkinson’s Disease, ALS, and pain further support the Buy rating, as these factors collectively indicate a strong growth trajectory for the company.
According to TipRanks, Biliouris is an analyst with an average return of -11.4% and a 33.49% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Legend Biotech, BioMarin Pharmaceutical, and Sarepta Therapeutics.
In another report released yesterday, RBC Capital also reiterated a Buy rating on the stock with a $95.00 price target.